Epidemiological Study to Describe Non-small-cell Lung Carcinoma (NSCLC) Clinical Management Patterns in MENA. Lung-EPICLIN/ KSA (EPICLIN)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01330862 |
Recruitment Status
: Unknown
Verified December 2012 by AstraZeneca.
Recruitment status was: Active, not recruiting
First Posted
: April 7, 2011
Last Update Posted
: December 12, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
NSCLC Patient Characteristics |
Study Type : | Observational |
Estimated Enrollment : | 54 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Epidemiological Study to Describe NSCLC Clinical Management Patterns in MENA. Lung-EPICLIN/ KSA |
Study Start Date : | April 2011 |
Estimated Primary Completion Date : | March 2013 |
Estimated Study Completion Date : | March 2013 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Confirmed NSCLC diagnosis (e.g. bronchoscope or FNAB), all stages, men and women, attending the responsible department of treating this type of patients for the first time between April 1st 2011 and March 31 2012, for PRO sub-sample: ability to read and write since they will be asked to participate in the PRO part of the study. Selection will not be based on the disease stage of each patient, in order to avoid a selection bias
Exclusion Criteria:
- According to the study design there will not be any exclusion criteria in order to provide a high validity and to obtain the most accurate real daily practice information.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01330862
Saudi Arabia | |
Research Site | |
Qassim, Central, Saudi Arabia | |
Research Site | |
Riyadh, Central, Saudi Arabia | |
Research Site | |
Dammam, Eastern, Saudi Arabia | |
Research Site | |
Jeddah, Western, Saudi Arabia |
Study Chair: | Dr. Abdul Rahman Jazieh | King Fahad National Guard Hospital | |
Principal Investigator: | Dr. Ahmed Abdulwarith | King Fahad Specialist Hospital | |
Principal Investigator: | Dr. Rasha Moastafa | King Fahad Medical City | |
Principal Investigator: | Dr. Sherif Wafa | Prince Faisal Bin Bander oncology centre | |
Principal Investigator: | Dr. Maged Mansour | Dr. Erfan & Bagedo Hospital | |
Principal Investigator: | Dr. Mohamed Rahhal | King Fahad Specialist Hospital |
Responsible Party: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT01330862 History of Changes |
Other Study ID Numbers: |
NIS-MENA-SA-IRS-2010/01 |
First Posted: | April 7, 2011 Key Record Dates |
Last Update Posted: | December 12, 2012 |
Last Verified: | December 2012 |
Keywords provided by AstraZeneca:
patient outcomes |
Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung Carcinoma, Bronchogenic Bronchial Neoplasms Lung Neoplasms Respiratory Tract Neoplasms |
Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases |